Breast Cancer Virtual Journal Club | Advances in Adjuvant Therapy for Endocrine Responsive Breast Cancer |
Expert perspectives with Robert E. Coleman, MD, FRCP; Stephen Jones, MD; and Janice Galleshaw, MD.
This independent medical education activity features an expert interview with Robert E. Coleman, MD, FRCP, and Stephen Jones, MD, covering important data from a recent publication focusing on the updated analysis of the Intergoup Exemestane Study (IES).
Drs Coleman and Jones briefly discuss the results of the updated analysis of the IES trial and clinical implications of switching adjuvant endocrine therapy to exemestane after 2-3 years of adjuvant tamoxifen to complete 5 years of treatment in postmenopausal women with breast cancer. |
|
Audience | This educational activity is designed for medical oncologists, surgical oncologists, radiation oncologists, and other healthcare providers involved and/or interested in the treatment of patients with breast cancer. The information on this site is intended for healthcare professionals based outside of the United States. |
|
|
Support | This educational activity is supported by Pfizer Oncology.
|
|
|
|
Featured Experts |
|
Featured Experts
|
 |
|
Robert E. Coleman, MD, FRCP
University of Sheffield
Sheffield, United Kingdom
|
| |
|
|
 |
|
Stephen Jones, MD
US Oncology
Houston, Texas, United States
|
| |
|
|
|
Interviewer
|
 |
|
Janice Galleshaw, MD
Medical Director
prIME Oncology
|
|
Activity Date | This Webcast is available from 4 November 2011 to 4 November 2012. |
|
